On May 22, 2026 SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, reported that the company and key collaborators will present data from three abstracts at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 Annual Meeting, taking place May 29 to June 2 in Chicago.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key poster presentations highlight the expanding body of evidence supporting Pathlight, SAGA’s tumor-informed structural variant (SV)-based circulating tumor DNA (ctDNA) platform, across both metastatic and localized settings. Retrospective analysis of PADA-1 samples will explore ctDNA kinetics during first-line therapy in metastatic breast cancer, while the real-world CITCCA cohort will evaluate Pathlight in colon and rectal cancer, through assessment of ctDNA clearance, recurrence risk, and outcomes in localized disease.
"As MRD testing becomes increasingly important in oncology, clinicians need assays capable of detecting patient-specific molecular residual disease at the lowest possible levels across a broad range of clinical settings," said Wendy Levin, MD, MS, Chief Clinical Officer at SAGA Diagnostics. "The data being presented at ASCO (Free ASCO Whitepaper) 2026 further highlight the potential of Pathlight’s ultrasensitive tumor-informed ctDNA approach to support treatment monitoring, recurrence assessment, and longitudinal disease surveillance across both metastatic and localized cancers."
Key SAGA Diagnostics Presentations During ASCO (Free ASCO Whitepaper) 2026:
Abstract Title
Presentation Details
ctDNA kinetics throughout first-line AI and palbociclib using a tumor-informed structural variant-based ctDNA assay: retrospective analysis of PADA-1 samples
Abstract: 3050
Poster: 187
Date: May 30, 2026
Time: 1:30 – 4:30 PM
Speaker: Luc Cabel, Institut Curie
Circulating Tumor DNA Clearance of Adjuvant Chemotherapy in Localized Colorectal Cancer Using an Ultrasensitive Structural Variant–Based Assay
Abstract: 3625
Poster: 392
Date: May 30, 2026
Time: 9:00 – 12:00 PM
Speaker: Cecilia Merk, MD, Karolinska Institutet
Localized Rectal Cancer Outcomes Predicted by ctDNA Analysis Using a Novel Ultrasensitive Structural Variant (SV)-based Method
Abstract: 3619
Poster: 386
Date: May 30, 2026
Time: 9:00 – 12:00 PM
Speaker: Cecilia Merk, MD, Karolinska Institutet
The full abstracts for SAGA Diagnostics at ASCO (Free ASCO Whitepaper) 2026 can be found here.
(Press release, SAGA Diagnostics, MAY 22, 2026, View Source [SID1234666024])